Drug intelligence / Profile preview

COVIBEL

Development stage: Phase 2
Lead developer: Nobel İlaç
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

COVIBEL is a virus-like particle (VLP) vaccine candidate developed for the prevention of COVID-19. It is the result of a collaborative effort between the Turkish pharmaceutical company Nobel Pharmaceuticals, the Scientific and Technological Research Council of Turkey (TÜBİTAK), Middle East Technical University (METU), and Bilkent University. The vaccine is designed to present SARS-CoV-2 viral antigens to the immune system using non-infectious particles that mimic the virus's structure but lack genetic material. This protein-based approach aims to trigger both humoral and cellular immune responses without the risks associated with live-attenuated or viral vector platforms. COVIBEL entered Phase 2 clinical development in 2021 and has been recognized on the World Health Organization's list of candidate vaccines.

Brand names: COVIBEL
Other names: Nobel VLP vaccineTÜBİTAK VLP vaccine

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on COVIBEL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIBEL.

Explore the full profile